COVID-19: FROM THE STRUCTURE AND REPLICATION CYCLE OF SARS-COV-2 TO ITS DISEASE SYMPTOMS AND TREATMENT

被引:21
作者
Zawilska, J. B. [1 ]
Lagodzinski, A. [2 ]
Berezinska, M. [3 ]
机构
[1] Med Univ Lodz, Dept Pharmacodynam, Lodz, Poland
[2] Med Univ Lodz, Dept Intervent Cardiol & Cardiac Arrhythmias, Lodz, Poland
[3] Med Univ Lodz, Dept Pharmacol & Toxicol, Lodz, Poland
来源
JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY | 2021年 / 72卷 / 04期
关键词
coronaviruses; SARS-CoV-2; COVID-19; multiorgan failure; inflammation; clinical symptoms; angiotensin converting enzyme 2; pro-inflammatory cytokines anti-COVID-19 medicines; vaccines; MULTISYSTEM INFLAMMATORY SYNDROME; RESPIRATORY-DISTRESS-SYNDROME; ACUTE KIDNEY INJURY; NEUROLOGICAL MANIFESTATIONS; STRESS-DISORDER; CORONAVIRUS; CHILDREN; MECHANISMS; INFECTION; SPECTRUM;
D O I
10.26402/jpp.2021.4.01
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
In December 2019, a small number of cases of pneumonia of unknown origin were recognized in the city of Wuhan, China. Soon, the disease, whose etiological factor was recognized as a coronavirus SARS-CoV-2, had spread across the world. The resulting CoV-associated diseases were classified by the WHO as COVID-19, and a pandemic was declared in March 2020. By 25 November 2021, there have been nearly 256.8 million of confirmed cases of COVID-19 around the world, including 5.17 million deaths. This review focuses on basal characteristics of the SARS-CoV-2 virus - its structure, replication cycle, variants and course of infection. It also briefly characterizes the currently recommended drugs and vaccines. Coronaviruses (CoVs) are a group of RNA viruses with a characteristic solar corona image observable on electron micrographs. SARS-CoV-2 possesses high affinity to human angiotensin converting enzyme 2 (ACE2) which serves as a cellular entry receptor. Its replication in human cells is accompanied by a high mutation rate. Six variants of SARS-CoV-2 have been found to be associated with essential changes of global public health significance; they are referred to as 'variants of concern' (VOC). The main route of transmission is through respiratory droplets. Although COVID-19 presents primarily as a respiratory disease, it can affect various other organs and systems that present the ACE2 protein to which the virus binds, including the heart, kidneys, intestines, liver, muscular and nervous system. COVID-19 infection can result in uncontrolled systemic hyperinflammation caused by release of a large amount of pro-inflammatory cytokines (a 'cytokine storm'), which can lead to multi-organ failure, rapid clinical deterioration and even death. Around 30% of those infected with SARS-CoV-2 remain asymptomatic, with the majority of patients demonstrating only mild or moderate symptoms; however, about 20% develop severe or critical disease. Three main groups of medications are currently recommended for therapy of COVID-19: monoclonal antibodies against the S protein of SARS-CoV-2, antiviral drugs and immunosuppressants which inhibit the cytokine storm. At present, the safest and most cost-effective way to prevent COVID-19 illness is a preventative vaccination.
引用
收藏
页码:479 / 501
页数:23
相关论文
共 50 条
  • [31] SARS-CoV-2 Infection and COVID-19 in Children
    Waghmare, Alpana
    Hijano, Diego R.
    CLINICS IN CHEST MEDICINE, 2023, 44 (02) : 359 - 371
  • [32] SARS-CoV-2: The Monster Causes COVID-19
    Song, Chang
    Li, Zesong
    Li, Chen
    Huang, Meiying
    Liu, Jianhong
    Fang, Qiuping
    Cao, Zitong
    Zhang, Lin
    Gao, Pengbo
    Nie, Wendi
    Luo, Xueyao
    Kang, Jianhao
    Xie, Shimin
    Lyu, Jianxin
    Zhu, Xiao
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2022, 12
  • [33] SARS-CoV-2 (COVID-19) superspreader events
    Majra, Dasha
    Benson, Jayme
    Pitts, Jennifer
    Stebbing, Justin
    JOURNAL OF INFECTION, 2021, 82 (01) : 36 - 40
  • [34] Rehabilitation with coronavirus disease with SARS-CoV-2 (COVID-19)
    Platz, Thomas
    Dewey, Stefan
    Koellner, Volker
    Schlitt, Axel
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2022, 147 (15) : 981 - 988
  • [35] Rehabilitation with coronavirus disease with SARS-CoV-2 (COVID-19)
    Platz, Thomas
    Dewey, Stefan
    Koellner, Volker
    Schlitt, Axel
    REHABILITATION, 2022, 61 (04) : 297 - 310
  • [36] From Cell to Symptoms: The Role of SARS-CoV-2 Cytopathic Effects in the Pathogenesis of COVID-19 and Long COVID
    Gonzalez-Garcia, Pablo
    Moreno, Ornella Fiorillo
    Penata, Eloina Zarate
    Calderon-Villalba, Alejandro
    Lugo, Lisandro Pacheco
    Hoyos, Antonio Acosta
    Camacho, Jose Luis Villarreal
    Quiroz, Roberto Navarro
    Londono, Leonardo Pacheco
    Martinez, Gustavo Aroca
    Moares, Noelia
    Gabucio, Antonio
    Fernandez-Ponce, Cecilia
    Garcia-Cozar, Francisco
    Quiroz, Elkin Navarro
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (09)
  • [37] SARS-CoV-2 reinfection and COVID-19 severity
    Nguyen, Nhu Ngoc
    Houhamdi, Linda
    Hoang, Van Thuan
    Delerce, Jeremy
    Delorme, Lea
    Colson, Philippe
    Brouqui, Philippe
    Fournier, Pierre-Edouard
    Raoult, Didier
    Gautret, Philippe
    EMERGING MICROBES & INFECTIONS, 2022, 11 (01) : 894 - 901
  • [38] Airborne transmission of SARS-CoV-2 disease (COVID-19)
    Parvez, Mohammad K.
    Parveen, Shama
    FUTURE VIROLOGY, 2022, 17 (05) : 261 - 264
  • [39] SARS-CoV-2: Remarks on the COVID-19 Pandemic
    Piasecki, Egbert
    ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2020, 68 (06)
  • [40] SARS-CoV-2 and COVID-19: A perspective from environmental virology
    Demoliner, Meriane
    Gularte, Juliana Schons
    Girardi, Viviane
    de Almeida, Paula Rodrigues
    Weber, Matheus Nunes
    Antunes Eisen, Ana Karolina
    Fleck, Juliane Deise
    Spilki, Fernando Rosado
    GENETICS AND MOLECULAR BIOLOGY, 2021, 44 (01)